Table 1.
Functional analysis of the antibody microarray data obtained from PSC secretome upon TNF-α treatment.
| Functional Annotation | p-Value | Predicted Activation State | z-Score | Molecule Number | Typical Molecules |
|---|---|---|---|---|---|
| Invasion of cells | 1.21E-23 | Increased | 2.952 | 33 | CCL11, CSF2, CTGF, FGF2, FN1, IFNG, IGF1, IGF2, IL1B, IL6, TIMP1, TIMP2, TNF, VEGFA, VEGFB, VEGFC, VTN |
| Stimulation of connective tissue cells | 3.14E-19 | Increased | 2.951 | 12 | CSF2, FGF2, IFNG, IGF1, IL10, IL1B, IL4, IL6, TNF, VEGFA |
| Generation of reactive oxygen species | 1.22E-13 | Increased | 2.884 | 15 | ALB, CSF2, IFNG, IGF1, IL10, IL1B, IL6, MMP14, SERPINB5, TNF |
| Migration of cells | 1.54E-39 | Increased | 2.876 | 58 | CCL11, CCL4, CSF2, CTGF, FGF1, FGF2, FN1, IGF1, IL4, IL6, MMP10, MMP11, MMP12, MMP14, TGFBI, THBS2, TIMP1, TIMP2, TNF, VEGFA, VEGFB, VEGFC, VTN |
| Proliferation of fibroblasts | 8.27E-14 | Increased | 2.747 | 17 | CTGF, DCN, FGF1, FGF2, FN1, IGF1, IGF2, IGFBP3, IL1B, IL4, IL6, TNF, |
| Growth of tumour | 3.50E-31 | Increased | 2.745 | 38 | CCL11, CSF2, CTGF, FGF1, FGF2, FN1 |
| Proliferation of lymphoma cell lines | 1.08E-13 | Increased | 2.739 | 13 | CCL11, IFNG, IGF1, IGF2, IGFBP1, IGFBP3, IL10, IL15, IL2, IL4, IL6, TF, TNF |
| Activation of fibroblasts | 6.06E-14 | Increased | 2.563 | 8 | ENO1, IFNG, IGF1, IGFBP3, IL6, VEGFB |
| Invasion of tumour cell lines | 3.90E-18 | Increased | 2.515 | 25 | CCL11, FGF2, FN1, MMP14, SERPINB5, TIMP1, TIMP2, TNF, VEGFA, VEGFB |
| Growth of malignant tumour | 6.38E-24 | Increased | 2.412 | 27 | FGF1, FGF2, GRN, IL10, IL12A, IL15, IL1AIL6, KLK3, TNF, |
| Cell movement of tumour cell lines | 1.63E-26 | Increased | 2.370 | 35 | AREG, CCL11, CCL4, CSF2, CTGF, CXCL10, CXCL8, CXCL9, DCN, FGF1, FGF2, |
| Migration of tumour cell lines | 4.10E-27 | Increased | 2.364 | 33 | AREG, CCL11, CSF2, CTGF, CXCL10, CXCL8, MMP14, SERPINE1, TGFBI, THBS2, TIMP1, TIMP2, TNF, VEGFA |
| Proliferation of tumour cell lines | 1.58E-24 | Increased | 2.339 | 42 | IL10, IL12A, IL1B, IL1RN, IL2, IL32, INS |
| Mitogenesis | 1.18E-22 | Increased | 2.315 | 19 | FGF1, FGF2, GRP, IGF1, IGF2, IGFBP2 |
| Proliferation of antigen presenting cells | 1.11E-17 | Increased | 2.225 | 13 | ENO1, EWSR1, FGF1, FGF2, FLNA, FN1, CSF2, DCN, IFNA1/IFNA13, IFNG, IGF1, IL10 |
| Formation of cells | 8.35E-15 | Increased | 2.219 | 27 | ADCYAP1, ALB, AREG, BGN, CCL11, CCL4, CSF2, CTGF, CXCL10 |
| Proliferation of cells | 3.78E-24 | Increased | 2.150 | 59 | FGF2, FN1, FRZB, GRN, GRP, GSN, IFNA1, IFNA13, IFNG, IGF1, IGF2, IGFBP1, IGFBP2, IGFBP3, IL10, IL12A, IL15, IL1A, IL1B, IL1RN, IL2, IL32, IL4 |
| Activation of cells | 8.99E-30 | Increased | 2.142 | 41 | TF, TG, TIMP1, TNF, TNFSF14, VEGFA, VTN |
| Proliferation of tumour cells | 2.73E-34 | Increased | 2.130 | 35 | IGFBP3, IL10, IL12A, IL15, IL1A, IL1B, IL1RN, IL2, IL32, IL4, IL6, KLK3 |
| Proliferation of immune cells | 2.18E-20 | Increased | 2.042 | 30 | ALB, CCL11, CCL4, CSF2, CTGF, CXCL10 |
| Proliferation of leukocyte cell lines | 8.60E-20 | Increased | 2.032 | 18 | CSF2, FGF1, FGF2, FN1, IFNG, IGF1 |
| Proliferation of cancer cells | 5.56E-22 | Increased | 2.020 | 24 | AREG, CSF2, CXCL8, DCN, FGF1, FGF2, GRN |
| Apoptosis of cancer cells | −1.27E-14 | Decreased | −2.578 | 15 | ALB, CSF2, FGF2, IFNG, IGF1, IGFBP3, IL10, IL15, IL4, IL6, MMP11, TF, TNF, VEGFA, VEGFC |
| Apoptosis of tumour cells | −8.67E-21 | Decreased | −2.882 | 21 | FGF2, IFNG, IGF1, IGFBP3, IL10, IL15, IL2, IL4, IL6, KLK3, MMP11, TF, TNF, VEGFA, VEGFC |
| Necrosis of tumour | −1.42E-24 | Decreased | −3.598 | 26 | IL1B, IL2, IL4, IL6, KLK3, MMP11, SERPINB5, SERPINE1, TF, THBS2, TIMP1, TIMP2, TNF, VEGFA, VEGFC |
| Cell death of tumour cells | −1.92E-23 | Decreased | −3.598 | 25 | CSF2, CXCL8, FGF2, IFNG, IGF1, IGFBP3, IL10, IL15, IL1A, IL1B, IL2, IL4, IL6, KLK3, MMP11, SERPINB5, SERPINE1, TF, THBS2, TIMP1, TIMP2, TNF, VEGFA, VEGFC |